Insulet Corporation PODD
This picture changes. Follow Insulet Corporation free — email when the signal or risk changes + a Sunday weekly brief.
Follow Insulet Corporation freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 7 Aug 2026
Latest news check: 6 Jun 2026
General analysis — not personal advice.
HOLD
6/10
Confidence
Existing position can be maintained pending clarity on US retention and Q3 results.
Strong fundamentals and profitability are weighed against lowered US guidance and execution risks, supporting a cautious hold stance.
Market sentiment
4/10
↓
Trend: Declining
The market is focused on the lowered guidance and escalating legal risks, creating strongly negative momentum.
Price context
The stock trades 62 % below its 52-week high after a sharp decline, reflecting market concern over US growth slowdown while also indicating that much of the uncertainty is already priced in.
Risk assessment
7/10
Dilution:
Low
Positive cash flow and strong cash position reduce need for new equity.
Jurisdiction:
Low
Operations primarily in the US and Europe.
Execution:
High
Repeated onboarding issues and recalls highlight operational challenges.
About the company
Insulet develops and sells tubeless insulin pumps under the Omnipod brand. The company is profitable with strong growth but recently lowered its US outlook due to onboarding issues for type 2 patients.
Sector:
Medical devices, diabetes treatment with insulin pumps
Type:
Biotech
Next report
15 Nov 2026
Q3
Catalysts
31 Aug 2026
Class action lead plaintiff deadline
High
Q4 2026
Q3 report
High
Horizon:
Bull case
International expansion and Omnipod 5 growth can offset weaker US sales.
Bear case
Lowered US guidance, recalls and class actions create ongoing uncertainty and negative momentum.
Sensitivity analysis
| Factor | If it weakens | If it strengthens |
|---|---|---|
| US Type 2 onboarding | Continued issues with type 2 patients → lower growth and sustained margin pressure. | Improved US retention → stabilized guidance and recovery in confidence. |
| Product quality and recalls | New quality issues → higher costs and regulatory hurdles. | Successful handling of recalls → reduced legal risk and stronger brand. |
We monitor these factors. Follow the company to get email when any of them hit.
Signal rationale (informational)
Strong fundamentals and profitability are weighed against lowered US guidance and execution risks, supporting a cautious hold stance.
Recent news
- The Q2 report beat estimates but the company lowered its full-year US sales guidance. The stock plunged over 20 % after the report. Several law firms have initiated class actions linked to the spring recall of seven million units.
Key figures
Revenue
Q2 2026
USD 802M
EBITDA
Q2 2026
USD 200M
Net income
Q2 2026
USD 95.0M
Cash
Q2 2026
USD 535M
Total debt
Q2 2026
USD 948M
Gross margin
Q2 2026
70.2%
Shares outstanding
2026-07-29
69.4M
EPS
Q2 2026
USD 1.37
Price & valuation
Last close
USD 143
Market Cap
USD 9.9B
1 week
+7.2 %
3 months
-4.0 %
12 months
-53.9 %
From 52w high
-59.5 %
From 52w low
+7.2 %
Exchange
NASDAQ
Type
Biotech
Sector
Medical devices, diabetes treatment with insulin pumps
This picture changes. Follow Insulet Corporation free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.